Journal: bioRxiv

Article Title: Improving the production and virulence of entomopathogenic fungi for biological control using insect-derived in vitro culture medium

doi: 10.64898/2026.03.14.711814

Figure Lengend Snippet: Four isolates of each species were used and grown on three locust-derived media (A – C) and the ¼ SDAY control medium (D). Medium A represents the twice filtered locust medium, Medium B represents the once filtered locust medium, and Medium C represents the unfiltered locust medium. Over the course of 7 days, radial growth and sporulation were monitored using a Reshape imaging robot. Thereafter, conidia were harvested to measure spore count, germination rate, and maximum growth in ¼ SDY medium using an oCelloscope TM imaging system. Lastly, pathogenicity assays were conducted using selected M. brunneum isolates on using Tenebrio molitor larvae.

Article Snippet: Each isolate x medium of origin combination was plated in triplicate and the oCelloScope Imaging system (BioSense Solutions, Denmark) was used to track the germination and growth of the isolates over the course of 48 hours.

Techniques: Derivative Assay, Control, Imaging

Journal: Molecular Pain

Article Title: Systemic curcumin administration mitigates neuropathic pain in a rat model of trigeminal neuralgia by suppressing TNF-α and pSTAT3 signaling

doi: 10.1177/17448069261445281

Figure Lengend Snippet: GFAP expression across all groups. (a) The immunoreactivity of GFAP in IONC + curcumin group is decreased in the rat trigeminal ganglia after injection of curcumin (GFAP: green, DAPI: blue). (b) The intensity of GFAP is measured using corrected total cell fluorescence and showed a significantly lower intensity in IONC + curcumin group compared to IONC and IONC + vehicle groups. (c) mRNA expression of GFAP decreases after curcumin administration. Data are presented as mean ± SEM. Immunofluorescence staining, n = 3. qRT-PCR, n = 6. ** p < 0.005. Scale bar 50 µm.

Article Snippet: This was followed by overnight incubation at 4°C with anti-GFAP polyclonal antibody (1:500; Bioss Antibody, Boston, MA, USA), anti-ATF3 monoclonal antibody (1:500; Santa Cruz, CA, USA) and anti-phospho-STAT3 monoclonal antibody (1:100; Cell Signaling Technology, Denver, MA, USA).

Techniques: Expressing, Injection, Fluorescence, Immunofluorescence, Staining, Quantitative RT-PCR